secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001213900-24-086079
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharmaceuticals launches 9-month promotional pilot for ARAKODA malaria drug
--------------------------------------------------------------------------------

- Nine-month pilot includes virtual sales reps and co-pay program to boost ARAKODA awareness and sales.
- ARAKODA is the only FDA-approved antimalarial covering all stages of malaria, with weekly dosing.
- Company plans expanded U.S. sales effort in 2025 based on pilot data.
- CEO Geoffrey Dow says pilot will inform how healthcare professionals view ARAKODA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024086079/0001213900-24-086079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024086079/ea0217026-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-086079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer